Stockscreener 앱 받기
0.6031
1.36%
-0.0083
시장 영업 전:
.60
-0.0031
-0.51%
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-04-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Therapeutics Inc (MEX:VTGN) Stock Price & 30 Year Financial Data - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
Vistagen Therapeutics, Inc. Files Form 8-K with SEC – Company Information, Address, and Stock Details (April 2026) - Minichart
Vistagen Therapeutics grants stock options to executives and employees - Investing.com
VistaGen Therapeutics Grants Broad Employee Retention Stock Options - TipRanks
Vistagen awards stock options to CEO Shawn K. Singh and CFO Nick B. Tressler - TradingView — Track All Markets
[8-K] Vistagen Therapeutics, Inc. Reports Material Event - Stock Titan
Institution Moves: Will Vistagen Therapeutics Inc outperform during market ralliesPortfolio Growth Summary & AI Forecasted Entry and Exit Points - baoquankhu1.vn
2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse
Trading Recap: What is the next catalyst for Vistagen Therapeutics IncInsider Selling & Low Volatility Stock Suggestions - baoquankhu1.vn
Vistagen Therapeutics Inc (MEX:VTGN) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Vistagen Therapeutics Inc a potential multi bagger2026 Reactions & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Hedge Fund Bets: Can Vistagen Therapeutics Inc sustain earnings growthMarket Volume Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Quarterly Risk: Can Vistagen Therapeutics Inc sustain earnings growth2026 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Vistagen Therapeutics Inc (MEX:VTGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Vistagen (VTGN) CFO awarded 75,000 stock options at $0.5358 - Stock Titan
Vistagen (NASDAQ: VTGN) CEO receives 75K stock options grant - Stock Titan
Vistagen (VTGN) awards stock options to its Chief Legal Officer - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bull Run: Should value investors consider Vistagen Therapeutics Inc2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
VistaGen Faces Nasdaq Audit Committee Compliance Setback - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
Vistagen Therapeutics notifies Nasdaq of audit committee non-compliance By Investing.com - Investing.com Canada
Vistagen Therapeutics notifies Nasdaq of audit committee non-compliance - investing.com
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Risk Report: Will Vistagen Therapeutics Inc outperform during market ralliesPortfolio Gains Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-31 | Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation | NDAQ:VTGN | Press Release - Stockhouse
Pullback Watch: What is the next catalyst for Vistagen Therapeutics IncShort Setup & Weekly Top Performers Watchlists - baoquankhu1.vn
Vistagen Therapeutics Inc Stock Operating Data - GuruFocus
Geopolitics Watch: Will Vistagen Therapeutics Inc. outperform during market rallies2026 Opening Moves & Community Verified Trade Alerts - baoquankhu1.vn
Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says - Law360
Vistagen Therapeutics Inc Stock Baskets - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Vistagen Therapeutics (MEX:VTGN) Dividends Paid - GuruFocus
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - biospace.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Connect - ACCESS Newswire
If You Invested $1,000 in Vistagen Therapeutics Inc (VTGN) - Stock Titan
Momentum Shift: What is the implied volatility of Vistagen Therapeutics Inc2026 Technicals & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vistagen Therapeutics, Inc. Announces Resignation of Mary Rotunno as Director, Effective April 1, 2026 - marketscreener.com
Vistagen (NASDAQ: VTGN) director Mary Rotunno resigns from board effective April 1, 2026 - Stock Titan
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - ChartMill
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - FinancialContent
VistaGen at Stifel CNS Forum: Strategic Insights on Fasedienol By Investing.com - Investing.com Canada
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN)March 16, 2026 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Vistagen (NASDAQ: VTGN) details pherine CNS pipeline in new presentation - Stock Titan
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight - The Daily Tribune News
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Financial Times
0.45%
0.77%
자본화:
|
볼륨(24시간):